title: Pharmacogenomics of breast cancer therapy: an update.
abstract: Clinical and histopathologic characteristics of breast cancer have long played an important role in treatment decision-making. Well-recognized prognostic factors include tumor size, node status, presence or absence of metastases, tumor grade, and hormone receptor expression. High tumor grade, presence of hormone receptors, and HER2-positivity are a few predictive markers of response to chemotherapy, endocrine manipulations, and anti-HER2 agents, respectively. However, there is much heterogeneity of outcomes in patients with similar clinical and pathologic features despite equivalent treatment regimens. Some of the differences in response to specific therapies can be attributed to somatic tumor characteristics, such as degree of estrogen receptor expression and HER2 status. In recent years, there has been great interest in evaluating the role that pharmacogenetics/pharmacogenomics, or variations in germline DNA, play in alteration of drug metabolism and activity, thus leading to disparate outcomes among patients with similar tumor characteristics. The utility of these variations in treatment decision-making remains debated. Here we review the data available to date on genomic variants that may influence response to drugs commonly used to treat breast cancer. While none of the variants reported to date have demonstrated clinical utility, ongoing prospective studies and increasing understanding of pharmacogenetics will allow us to better predict risk of toxicity or likelihood of response to specific treatments and to provide a more personalized therapy.
authors.affiliation: Duke University Medical Center, Duke Cancer Institute, Breast Cancer Program, DUMC Box 3893, 10 Searle Dr., Sealy Mudd Bldg. Room 449A, Durham, NC 27710, United States. Kelly.mitchell@duke.edu
authors.forename: Kelly
authors.initials: K
authors.lastname: Westbrook
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D020845:Selective Estrogen Receptor Modulators